Print this page
Multiple Myeloma
-
The Rutgers University study of the Genetics of Blood Cancers
Protocol: 002606Principal Investigator:
- Tara Matise
Applicable Disease Sites: Hodgkin's Lymphoma
Leukemia, not otherwise specified
Leukemia, other
Lymphoid Leukemia
Multiple Myeloma
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Hematopoietic -
The Rutgers University study of the Genetics of Blood Cancers
Protocol: 002606Principal Investigator:
- Tara Matise
Applicable Disease Sites: Hodgkin's Lymphoma
Leukemia, not otherwise specified
Leukemia, other
Lymphoid Leukemia
Multiple Myeloma
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Hematopoietic -
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.
Protocol: 011910Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Bones and Joints
Ill-Defined Sites
Multiple Myeloma -
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
Protocol: 012108Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Hodgkin's Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma -
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.
Protocol: 011910Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Bones and Joints
Ill-Defined Sites
Multiple Myeloma -
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
Protocol: 012108Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Hodgkin's Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma -
A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.
Protocol: 012204Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Multiple Myeloma -
A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.
Protocol: 012204Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Multiple Myeloma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/2 Study of ABBV-383 in Combination with Anti-Myeloma Agents for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma.
Protocol: 012502Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 1/2 Study of ABBV-383 in Combination with Anti-Myeloma Agents for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma.
Protocol: 012502Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma
- 1
- 2